BRPI0910118A2 - antagonistas de receptores do glucagon - Google Patents

antagonistas de receptores do glucagon

Info

Publication number
BRPI0910118A2
BRPI0910118A2 BRPI0910118A BRPI0910118A BRPI0910118A2 BR PI0910118 A2 BRPI0910118 A2 BR PI0910118A2 BR PI0910118 A BRPI0910118 A BR PI0910118A BR PI0910118 A BRPI0910118 A BR PI0910118A BR PI0910118 A2 BRPI0910118 A2 BR PI0910118A2
Authority
BR
Brazil
Prior art keywords
receptor antagonists
glucagon receptor
glucagon
antagonists
receptor
Prior art date
Application number
BRPI0910118A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Ihor Korytko
Brian John Ondek
Rohn Lee Junior Millican
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40794248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0910118(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0910118A2 publication Critical patent/BRPI0910118A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910118A 2008-03-27 2009-03-17 antagonistas de receptores do glucagon BRPI0910118A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3990708P 2008-03-27 2008-03-27
PCT/US2009/037349 WO2009120530A1 (en) 2008-03-27 2009-03-17 Glucagon receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0910118A2 true BRPI0910118A2 (pt) 2015-12-29

Family

ID=40794248

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910118A BRPI0910118A2 (pt) 2008-03-27 2009-03-17 antagonistas de receptores do glucagon

Country Status (15)

Country Link
US (2) US7968686B2 (enExample)
EP (1) EP2268670A1 (enExample)
JP (1) JP5438095B2 (enExample)
KR (1) KR101235934B1 (enExample)
CN (1) CN101983208A (enExample)
AR (1) AR070844A1 (enExample)
AU (1) AU2009228866A1 (enExample)
BR (1) BRPI0910118A2 (enExample)
CA (1) CA2719761A1 (enExample)
CL (1) CL2009000586A1 (enExample)
EA (1) EA201071126A1 (enExample)
MX (1) MX2010010517A (enExample)
PE (1) PE20091674A1 (enExample)
TW (1) TW201000126A (enExample)
WO (1) WO2009120530A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2475683A4 (en) * 2009-09-08 2013-04-24 Neopharm Co Ltd GLUCAGONIC RECEPTOR ANTIBODY YOUR USE
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
JP2015505828A (ja) 2011-12-02 2015-02-26 イーライ リリー アンド カンパニー 抗グルカゴン抗体およびその使用
CN105189560A (zh) * 2013-05-07 2015-12-23 瑞纳神经科学公司 抗胰高血糖素受体抗体和其使用方法
EP3151855B1 (en) * 2014-06-08 2021-11-24 REMD Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
SG10201913074WA (en) 2016-08-30 2020-03-30 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
JP7005638B2 (ja) 2017-01-27 2022-02-04 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド グルカゴン受容体結合タンパク質及びその使用方法
US12139546B2 (en) 2017-08-22 2024-11-12 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
US20220153853A1 (en) 2018-12-21 2022-05-19 Jiangsu Hengrui Medicine Co., Ltd. Bispecific protein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
JP3515112B2 (ja) 1992-08-28 2004-04-05 ノボ ノルディスク アクティーゼルスカブ グルカゴン・レセプタ
US6909031B2 (en) 2000-12-06 2005-06-21 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
AR036711A1 (es) * 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
EP2034916A1 (en) 2006-07-04 2009-03-18 Bracco Imaging S.p.A Device for localized thermal ablation of biological tissue, particularly tumoral tissues or the like
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Also Published As

Publication number Publication date
CL2009000586A1 (es) 2010-06-04
US7968686B2 (en) 2011-06-28
MX2010010517A (es) 2010-12-20
CN101983208A (zh) 2011-03-02
US20090252727A1 (en) 2009-10-08
EA201071126A1 (ru) 2011-04-29
AR070844A1 (es) 2010-05-05
JP2011518125A (ja) 2011-06-23
KR20100117130A (ko) 2010-11-02
CA2719761A1 (en) 2009-10-01
TW201000126A (en) 2010-01-01
AU2009228866A1 (en) 2009-10-01
PE20091674A1 (es) 2009-11-04
KR101235934B1 (ko) 2013-02-21
EP2268670A1 (en) 2011-01-05
JP5438095B2 (ja) 2014-03-12
WO2009120530A1 (en) 2009-10-01
US20110212092A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0910592A2 (pt) antagonistas de receptor 2 de somatostatina
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
DK2129654T3 (da) Antagonister af glucagonreceptoren
EP1981902A4 (en) NOGO RECEPTOR ANTAGONISTS
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
BRPI0918004A2 (pt) antagonistas de glucagon
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
DK2370461T3 (da) Glucagonanaloger
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
BRPI0923512A2 (pt) antagonistas de receptores de ácido lisofosfatídico
DK2081951T3 (da) Progesteron-receptorantagonister
BRPI0823377A2 (pt) análogos de glucagon
BRPI0823378A2 (pt) análogos de glucagon
BRPI0823376A2 (pt) Análagos de glucagon
DK2009992T3 (da) Il-8 receptor-antagonister
EP2362779A4 (en) CXCR4 RECEPTOR COMPOUNDS
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
BRPI0810926A2 (pt) Antagonista de crig
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
BRPI0817835A2 (pt) Antagonistas cgrp
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.